Surrozen, Inc. (SRZN) Stock

Surrozen, Inc. (SRZN) is a Healthcare stock trading at $23.96 (as of 2026-08-21), with a market capitalization of $278.18M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Surrozen, Inc. is a biotechnology company developing drug candidates that selectively modulate the Wnt signaling pathway, including tissue-targeted antibody approaches. Its pipeline includes SZN-043, a tissue-specific R-spondin mimetic for severe liver disease, and SZN-1326, a bispecific human antibody targeting receptors involved in Wnt signaling in intestinal crypts, with potential applications across multiple disease areas.

Understand Surrozen, Inc.: how it makes money

Surrozen develops tissue-specific antibody drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration, it makes money mainly through collaboration and license revenue tied to its drug development programs.

This profit model is driven by development-stage funding, with current revenue coming from collaborations and licenses rather than commercial product sales, so future sales depend on clinical progress of its Wnt-pathway antibody candidates.

Revenue by segment (latest quarter)
Collab&License$0.0B
RelatedPartyR&D$0.0B

Business quality (Weak): Early-stage biotech with very small current revenue, ongoing clinical enrollment, and a deeply negative operating margin, upside depends on whether its tissue-specific Wnt modulators advance into later-stage clinical success and eventual product revenue.

Bull case

  • Pipeline targets the Wnt pathway with tissue-specific antibodies for tissue repair and regeneration: Its development focus is tissue-specific R-spondin mimetics and Wnt-modulating full-length human antibodies, with application across multiple disease areas.
  • Clinical activity is underway in Phase 1a: The company reports enrollment of 40 healthy volunteers and 8 cirrhotic patients in Phase 1a trial.

Bear case

  • Current revenue base is extremely small: For the latest reported period, total revenue is shown as 0.0B, with collaboration and license revenue reported at 0.01B and research service revenue from a related party at 0.0B.
  • Operating losses are very large: The latest quarter shows an operating margin of -209.1%, reflecting ongoing costs before meaningful commercial revenue.
Valuation — source: SEC EDGAR (first-party)
Price$23.96
Market Cap$278.18M
Price / Sales35.00
FCF Yield-22.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$3.48M
Net Margin-6960.8%
Revenue Growth (YoY)-67.4%
EPS Growth (YoY)49.4%
FCF Growth (YoY)72.0%
Financial Health — source: SEC EDGAR
Altman Z-Score-7.28 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderColumn Group LLC ($55.84M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOCraig C. Parker
Employees40
CountryUS
IPO Date2021-01-11

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Sutro Biopharma, Inc. (STRO)
  • Agenus Inc. (AGEN)
  • Inhibikase Therapeutics, Inc. (IKT)
  • Neumora Therapeutics, Inc. Common Stock (NMRA)
  • Anavex Life Sciences Corp. (AVXL)
  • SAB Biotherapeutics, Inc. (SABS)
  • Fate Therapeutics, Inc. (FATE)
  • Lineage Cell Therapeutics, Inc. (LCTX)
SRZN earnings history · SRZN institutional & insider holders · SRZN KPIs & operating metrics · SRZN financials · SRZN investor presentations & press releases · SRZN SEC filings · SRZN peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.